- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00299026
A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent
March 1, 2017 updated by: Boston Scientific Corporation
TAXUS II: A Randomized, Double-Blind, Controlled Study of the Safety and Performance of the NIRx™ Paclitaxel-Coated Conformer Coronary Stent
The clinical investigation is an international, prospective, double-blind, randomized safety and efficacy study.
The purpose of this study is to evaluate the safety and performance of the NIRx(TM) Paclitaxel-Coated Stent (1.0µg/mm2 of paclitaxel incorporated into slow- and moderate-release formulation of a triblock copolymer carrier system)in patients who present for stenting of de novo lesions of a native coronary artery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to evaluate the safety and performance of coronary artery stenting with the NIRx(TM) Paclitaxel-Coated Stent (1.0µg/mm2 of paclitaxel incorporated into slow- and moderate-release formulation of a triblock copolymer carrier system) for the treatment of de novo lesions in native vessels.
Patients in 2 sequential cohorts will be randomised to receive either the NIRx(TM) Paclitaxel-Coated Stent or the uncoated control stent.
In cohort 1, the slow-release formulation NIRx(TM) Paclitaxel-Coated Stent will be studied.
If the safety profile is acceptable, the moderate-release formulation NIRx(TM) Paclitaxel-Coated Stent will be studied in Cohort 2. In each f the 2 cohorts, 133 patients will be treated with the NIRx(TM) paclitaxel-Coated Stent and 133 with the uncoated control stent (1.1 ratio), for a total of 532 patients in study.
Study Type
Interventional
Enrollment
532
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milano, Italy, 20132
- San Raffaele del Monte Tabor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
General Inclusion Criteria:
- Patient >= 18 years old.
- Eligible for percutaneous transluminal coronary angioplasty (PTCA).
- Patient (or legal guardian) understands the study requirements and the stent treatment procedure and provides written Informed Consent before any study-specific tests or procedures are performed.
- Willing to comply with all specified follow-up evaluations.
- Documented stable angina pectoris (Canadian Cardiovascular Society Classification [CCS] 1, 2, 3, or 4), unstable angina pectoris with documented ischemia (Braunwald Class IB - C, IIB - C, or IIIB - C), or documented silent ischemia.
- Acceptable candidate for CABG.
Angiographic Inclusion Criteria:
- Target lesion is located within a native coronary vessel.
- Target lesion is de novo (i.e., a coronary lesion not previously treated).
- Target lesion diameter stenosis >= 50% and <= 99% (visual estimate or on-line QCA).
- Target lesion <= 12 mm in length (visual estimate or on-line QCA).
- Target vessel >= 3.0 mm and <= 3.5 mm in diameter (visual estimate or on-line QCA).
General Exclusion Criteria:
- Known sensitivity to paclitaxel.
- Patient has received paclitaxel or other anti-mitogenic agent within 12 months prior to planned enrollment in the study.
- Patient has previous stent procedure with any drug-coated or drug-eluting stent device.
- Patient has undergone any coronary intervention within 30 days prior to stent placement associated with this protocol.
- Patient anticipates planned additional intervention (staged procedure) to any non-target coronary vessel within 45 days after the stent placement associated with this protocol.
- MI within 72 hours of planned stent placement.
- Left ventricular ejection fraction (LVEF) of < 30%.
- Stroke within the past 6 months.
- Acute or chronic renal dysfunction (creatinine >1.7 mg/mL or >150 µmol/L).
- Acetylsalicylic acid and/or clopidogrel and/or ticlopidine are contraindicated.
- Leukopenia (leukocytes <3.5 x 109/liter).
- Thrombocytopenia (platelets <100,000/mm3).
- Active peptic ulcer or active gastrointestinal (GI) bleeding.
- Known allergy to stainless steel.
- Previously enrolled in the NIRx(TM) Coronary Stent Clinical Safety and Performance Study.
- Currently enrolled in another investigational device or drug study and has not completed the required follow-up period, or has completed all other study-required follow-up less than 30 days prior to enrollment in this study.
- Patient is lactating, has a positive pregnancy test within 7 days of planned stent placement, or intends to become pregnant during the study (only applies to female patients of child-bearing potential).
- Life expectancy of less than 24 months because of other medical conditions.
- Co-morbid condition(s) that could limit the patient's ability to participate in the study or comply with follow-up requirements or co-morbid condition(s) that could impact the scientific integrity of the study.
Angiographic Exclusion Criteria:
- Unprotected left main coronary artery disease (or obstruction greater than 50% in the left main coronary artery that is not protected by at least 1 non-obstructed bypass graft to the left anterior descending [LAD] or circumflex artery or a branch thereof).
- Target lesion is in a previously stented segment.
- Target vessel was treated with directional coronary atherectomy, laser, or transluminal extraction catheter prior to stent placement.
- Target lesion is ostial in location (within 3 mm of vessel origin).
- Target site of stent placement has side branches >2.0 mm in diameter.
- Target lesion is severely calcified (by visual estimate)
- Target vessel has closed abruptly or is threatening closure.
- Target lesion is located within or immediately distal to a >60° bend in the vessel.
- Target vessel has diffuse disease requiring more than one 15 mm stent for full lesion coverage.
- Target lesion involves a bifurcation where a branch vessel greater than 2.0 mm in diameter originates (either stenosis of both main vessel and major branch or stenosis of just major branch).
- Target lesion has excessive tortuosity unsuitable for stent delivery and deployment.
- Target lesion is located within a saphenous vein bypass graft.
- Target lesion is located in a vessel section supplied by distal graft.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Mean percent in-stent net volume obstruction at 6 months post-procedure as measured by IVUS
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Antonio Colombo, MD, Ospedale San Raffaele del Monte Tabor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2001
Primary Completion (Actual)
May 1, 2003
Study Completion (Actual)
February 1, 2007
Study Registration Dates
First Submitted
March 3, 2006
First Submitted That Met QC Criteria
March 3, 2006
First Posted (Estimate)
March 6, 2006
Study Record Updates
Last Update Posted (Actual)
March 3, 2017
Last Update Submitted That Met QC Criteria
March 1, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Artery Disease
- Myocardial Ischemia
- Coronary Disease
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- TAXUS II
- S2003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System
-
Medtronic VascularCompletedCoronary Artery DiseaseKorea, Republic of, Spain, Australia, Hong Kong, United Kingdom, Singapore, Thailand, Belgium, New Zealand, Sweden, France, Switzerland, Netherlands, Italy, Slovakia, Lithuania, Austria, Malaysia, Bulgaria, Ireland, Latvia, Norway, ...
-
Atrium Medical CorporationTerminatedCoronary Artery DiseaseBelgium
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery RestenosisUnited States
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary RestenosisNetherlands, Spain, Denmark, Germany, France, Austria, Belgium, India, Italy, New Zealand, Poland, South Africa, Switzerland
-
Abbott Medical DevicesCompletedCoronary Artery DiseaseUnited States
-
Cordis CorporationConor MedsystemsCompletedCoronary DiseaseUnited States
-
Cordis CorporationConor MedsystemsTerminatedCoronary AtherosclerosisBrazil, New Zealand
-
Medtronic VascularCompletedCardiovascular Diseases | Coronary Artery Disease | Arteriosclerosis | Ischemic Heart Disease | Stenotic Coronary LesionChina
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary RestenosisNew Zealand, Australia, Germany, France, Switzerland, Netherlands, United Kingdom, Portugal, Belgium, Denmark
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary RestenosisUnited States, Australia, New Zealand, Germany